title: Second malignancy in 597 patients with ewing sarcoma of bone treated at a single institution with adjuvant and neoadjuvant chemotherapy between 1972 and 1999.
abstract: The relative risk of second tumors in patients with Ewing sarcoma is controversial, and little is known about their treatment and outcome. The purpose of the current study was to define the incidence and features of second tumors among 597 long-term survivors of nonmetastatic Ewing sarcoma treated with adjuvant and neoadjuvant chemotherapy, radiotherapy, and/or surgery. The authors found that the risk of secondary malignancy after adjuvant or neoadjuvant treatment of Ewing sarcoma is higher than that after other childhood or adolescent cancers only after radiotherapy. Based on this, postoperative radiotherapy should be avoided when surgery with adequate margins is feasible.
authors.affiliation: Department of Chemotherapy, Musculoskeletal Oncology at Istituto Ortopedico Rizzoli, Bologna, Italy. gaetano.bacci@ior.it
authors.forename: Gaetano
authors.initials: G
authors.lastname: Bacci
authors.forename: Alessandra
authors.initials: A
authors.lastname: Longhi
authors.forename: Enza
authors.initials: E
authors.lastname: Barbieri
authors.forename: Stefano
authors.initials: S
authors.lastname: Ferrari
authors.forename: Mario
authors.initials: M
authors.lastname: Mercuri
authors.forename: Antonio
authors.initials: A
authors.lastname: Briccoli
authors.forename: Michela
authors.initials: M
authors.lastname: Versari
authors.forename: Elettra
authors.initials: E
authors.lastname: Pignotti
authors.forename: Piero
authors.initials: P
authors.lastname: Picci
mesh_terms: D000293:Adolescent; D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000473:pathology* / Q000628:therapy; D002648:Child; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000209:etiology; D016609:Neoplasms, Second Primary / Q000473:pathology* / Q000628:therapy; D012512:Sarcoma, Ewing / Q000473:pathology* / Q000628:therapy; D015996:Survival Rate; D017741:Survivors; D016896:Treatment Outcome